ArticleCancer biomarkers : section A of Disease markers2019
Inhibition of lncRNA PANDAR reduces cell proliferation, cell invasion and suppresses EMT pathway in breast cancer.
Article in Cancer biomarkers : section A of Disease markers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- CAF-derived exosomes: orchestrators of dysregulated signaling pathways in breast cancer progression.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- The diagnostic and predictive value of LncRNA PANDAR in gastric cancer and its regulation of gastric cancer progression via miR-637.Hereditas · 2025Article
- Dual-regulatory miRNAs: master regulators and therapeutic targets in bone-metastatic breast cancer.Frontiers in molecular biosciences · 2025Review
- The long non-coding RNA PANDAR regulates cell proliferation and epithelial-to-mesenchymal transition in glioma.Histology and histopathology · 2023Article
- Long non-coding RNAs as novel prognostic biomarkers for breast cancer in Egyptian women.Scientific reports · 2022Article
- Regulatory mechanism of miR-20a-5p expression in Cancer.Cell death discovery · 2022Review
- The Long Noncoding RNA MEG3 Retains Epithelial-Mesenchymal Transition by Sponging miR-146b-5p to Regulate SLFN5 Expression in Breast Cancer Cells.Journal of immunology research · 2022Article
- What is beyond LncRNAs in breast cancer: A special focus on colon cancer-associated Transcript-1 (CCAT-1).Non-coding RNA research · 2021Article
- Suppression of circulatingOncology letters · 2021Article
- Knockdown of LncRNA PANDAR by CRISPR-dCas9 Decreases Proliferation and Increases Apoptosis in Oral Squamous Cell Carcinoma.Frontiers in molecular biosciences · 2021Article
- Long non-coding RNA PART1 promotes intervertebral disc degeneration through regulating the miR‑93/MMP2 pathway in nucleus pulposus cells.International journal of molecular medicine · 2020Article
- Long noncoding RNACell cycle (Georgetown, Tex.) · 2020Article
- LncRNA GATA6-AS1 Inhibits the Progression of Non-Small Cell Lung Cancer via Repressing microRNA-543 to Up-Regulating RKIP.Cancer management and research · 2020Article
- Up-regulation of FAT4 enhances the chemosensitivity of colorectal cancer cells treated by 5-FU.Translational cancer research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe PANDAR, a novel identified long non-coding RNA, is previously reported to function as oncogene in various cancers including breast cancer. the study aims to explore the role of lncRNA PANDAR for cell proliferation and invasion of breast cancer, and its underlying mechanism.
methodsThe expression of lncRNA PANDAR in 65 pairs of breast cancer tissues and adjacent normal tissues was detected by quantitative Real-time polymerase chain reaction (qRT-PCR) assay. The association between lncRNA PANDAR expression and clinical factors of breast cancer was analyzed. Cell proliferation, cell colony formation and cell invasion assays were performed to detect the effects of lncRNA PANDAR expression tumor proliferation and invasion abilities. The western blot analysis was also performed to detected the EMT related makers expression of E-cadherin, Vimentin, MMP2 and MMP9.
resultsWe demonstrated that lncRNA PANDAR expression was higher in breast cancer tissues and cells compared with adjacent normal tissues and the normal mammary epithelial cell line, respectively. Higher lncRNA PANDAR expression positively associated with lymph node metastasis and advanced clinical stage in patients. In vitro, we demonstrated that knockdown of lncRNA PANDAR significantly suppressed cell proliferation, cell colony formation and cell invasion ability in breast cells. Furthermore, we verified that knockdown of lncRNA PANDAR dramatically inhibited cell epithelial-mesenchymal transition (EMT) pathway by downregulating Vimentin, MMP2 and MMP9 expression, but upregulating E-cadherin expression in breast cancer.
conclusionsOur results proved that PANDAR may serve as potential target of breast cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.